THE USE OF CONVALESCENT PLASMA IN THE TREATMENT OF THE NEW CORONAVIRUS DISEASE COVID-19: FIRST CLINICAL EXPERIENCE

Abstract

The article presents an analysis of the state of the problem of transfusion of convalescent plasma in case of new coronavirus disease COVID-19 based on a literature review, as well as our own clinical material based on the experience of treating 8 patients with this method. The rationale for the use of plasma in COVID-19 is the long-term experience of using immune plasma in a number of diseases caused by bacteria, viruses (diphtheria, tetanus, Ebola virus diseases, SARS-CoV-1, MERS, etc.) and the possibility of rapid administration of ready-made antibodies for passive immunization. The authors present the results of treatment of 8 patients with severe forms of coronavirus disease, positive results were obtained in 5 out of them. The issues of efficiency, the need to clarify the indications for the introduction of convalescent plasma and randomized clinical trials are discussed.